Welcome to InfiCure Bio

InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.

Based on a panel of in vivo models for these conditions including a proprietary model for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.

Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.

News

InfiCure Bio in New York

InfiCure Bio was one of eight Nordic companies presenting at the 29th Seed Forum in New York on Wednesday June 7th. Last Minute Brief was held at Nordic Innovation House, WeWork Grand Central, on Tuesday June [...]

Preparation for meeting in New York

InfiCure Bio is one of 9 Nordic companies which will meet with American investors in New York on 7th of June. The three Swedish companies are InfiCure Bio, Smartster and Poseidon. Yesterday, the Swedish companies met at [...]

Connect Company of 2016 in northern Sweden

InfiCure Bio is awarded Connect Company of 2016 in northern Sweden. There were 26 companies in the competition and the winner was announced at the annual meeting of Connect Norr. The company will besides the honor [...]

InfiCure Bio is 2016 Connect company in Västerbotten

InfiCure Bio was selected as 2016 Connect Company in Västerbotten at the annual meeting of Connect in Umeå. Five companies were nominated for the prize and the winner was chosen by the Board of Connect Sweden. InfiCure [...]